Citations

Citations to this article as recorded by  

• Correspondence to letter to the editor on “Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma”
  Hideki Iwamoto, Hironori Koga, Takumi Kawaguchi
  Clinical and Molecular Hepatology.2026; 32(3): e424.     CrossRef
• Correspondence to editorial on “Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma”
  Yang Liu, Fan Peng, Siyuan Wang, Jinliang Xing
  Clinical and Molecular Hepatology.2025; 31(2): e166.     CrossRef
• Reply to correspondence on “Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma”
  Hyuk Soo Eun
  Clinical and Molecular Hepatology.2025; 31(2): e215.     CrossRef